[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma":649},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,122,0,25,[9,46,104,130,151,220,243,271,293,314,335,359,381,401,423,439,458,477,495,520,543,564,583,606,629],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054254",false,"NCT07425535","Optic Nerve Head Strain in Non-glaucoma Subjects","Inclusion Criteria:\n\n* Adults who have no history of OAG\n* Have an ocular examination by a glaucoma specialist with no indications of OAG\n* Have normal optical coherence tomography findings in the retinal nerve fiber layer.\n* Over age 30 will be included from\n* Both sexes\n* All ethnic groups.\n* Optic neuropathy.\n* Both suspects and those with glaucoma damage will be included.\n* When both eyes meet inclusion and exclusion criteria, both eyes will be included in the study and statistical methods will be used to account for correlations between eyes within the same individual.\n\nExclusion Criteria:\n\n* in whom sitting in an upright position is impossible due to physical disability\n* with ocular media opacity, corneal scarring, cataract or vitreous hemorrhage, that does not allow adequate imaging resolution.\n* in whom keeping the eyes open during the imaging procedure is not possible or uncomfortable.\n* who cannot perform home tonometry accurately at certification\n* who do not have reliable clinical Optical Coherence Tomography (OCT) testing.\n* with any form of glaucoma\n* with high myopia defined as refractive error \\> -8\n* with past keratorefractive surgery, corneal dystrophy, or corneal ectasia that would make self-tonometry measurements difficult to interpret\n* inability to understand English or with a language or hearing impairment",true,"ALL","30 Years","90 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.",[27],"Glaucoma",[29,30,31,32],"optic nerve","biomechanical strain","normal eye","glaucoma","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-06-24",{"date":41,"type":21},"2028-03-31",{"name":43,"class":44},"Johns Hopkins University","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":69,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100619218","NCT07341763","Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments","Inclusion Criteria:\n\n* Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling.\n* Have binocular visual acuity or best corrected binocular visual acuity no worse than 6\u002F12 or 20\u002F40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance.\n* Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent.\n* Have read and fully comprehends the information in the consent letter.\n* Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule.\n\nExclusion Criteria:\n\n* Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study.\n* Have been diagnosed with dementia or self-reported dementia with no formal diagnosis.\n* Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis.\n* Have been diagnosed with physical or motor impairments resulting in walking and\u002For balancing issues or self-reported physical or motor impairments resulting in walking and\u002For balancing issues with no formal diagnosis.\n* Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and\u002For mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and\u002For mobility with no formal diagnosis.\n* Are unable to follow the researcher's instructions.\n* Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study.\n* Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and\u002For their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable.\n* Have severe hearing impairment.\n* Are pregnant or trying to get pregnant.\n* Fit any of the typical contraindicators for brain stimulation. See contraindicator section below.\n\nFor all participants the contraindications for brain stimulation are:\n\n* Diagnosed with epilepsy or have previously experienced an epileptic seizure.\n* Implanted medication pump or implanted electronic device, including defibrillator or pacemaker.\n* Any metal implants in the head (excluding tooth fillings).\n* Active electric implants anywhere in the body (especially the head region).\n* On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia.\n* Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face.\n* Recurring headaches.\n* Previous head injury or skull fracture or head\u002Fbrain surgery.\n* Heart disease, neurological condition, or a history of cardiac or neurological surgery.\n* Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.","18 Years",{"count":54,"type":21},20,[56],"NA","This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.",[59,60,61,62,63,64,65,66,67,68,27],"Retinitis Pigmentosa (RP)","Rod Cone Dystrophy","Visually Impaired Persons","Peripheral Visual Field Defect of Both Eyes","Low Vision, Both Eyes","Vision Loss Partial","Orientation","Mobility Difficulty","Mobility Limitation","Mobility and Independence",[59,70,71,61,62,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95],"Rod Cone dystrophy","Advanced Glaucoma","Low Vision, Both eyes","Brain stimulation","tES","tRNS","hf-tRNS","transcranial electrical stimulation","transcranial random noise stimulation","high-frequency transcranial random noise stimulation","Long white cane","white cane","mobility cane","walking","orientation and mobility","orientation","mobility","low vision","vision loss partial","occipital pole","primary visual cortex","V1","neuroplasticity","mobility difficulty","mobility limitation","mobility and independence","2026-06-30",{"date":98,"type":37},"2026-07-01",{"date":98,"type":21},{"date":101,"type":21},"2027-08-31",{"name":103,"class":44},"University of Waterloo",{"id":105,"slug":4,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":45},"100495044","NCT05726058","Ocular Blood Flow Imaging for Glaucoma Assessment","Inclusion Criteria:\n\n* Age 18 and older with binocular vision\n* Able to provide informed consent\n* Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria\n\nExclusion Criteria:\n\n* The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)\n* The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy\n* The subject has prior ocular disease other than glaucoma\n* The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye\n* The subject has more than 15 diopters of refractive error\n* The subject is a female who is pregnant or nursing\n* The subject has diabetes mellitus","88 Years",{"count":111,"type":21},150,[56],"The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.\n\nThe main question it aims to answer are:\n\n* Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?\n* Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring?\n\nParticipants will be\n\n* measured for their blood pressure, heart rate, height, and weight\n* dilated with tropicamide\n* imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry\n* imaged using the XyCAM RI while inhaling 100% oxygen through a mask",[27],[32,116,117,118,119,120,121],"xycam","blood flow","imaging","ophthalmology","retinal blood flow","eye disease",{"date":123,"type":37},"2026-07-02",{"date":125,"type":37},"2023-03-30",{"date":127,"type":21},"2028-04-30",{"name":129,"class":44},"University of Maryland, Baltimore",{"id":131,"slug":4,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":45},"100644778","NCT07674069","World Sight Foundation Field Machine (WSFFM) Pilot","Clinical Testing Pilot of the World Sight Foundation Field Machine (WSFFM) in Glaucoma Patients - Comparison With Humphrey Visual Field Analyser","WSFFM","Inclusion Criteria:\n\n* \\- Patients attending glaucoma outpatient clinic\n* Patients requiring visual field testing, with plan for \"SITA-STANDARD\" HVF testing\n* Patients 18 years or older and of any gender\n* Patients capable of giving informed consent.\n\nExclusion Criteria:\n\n* \\- Patients not requiring visual field testing on that outpatient clinic attendance.\n* Patients requiring visual field testing, with plan for \"SITA-FAST\" or \"SITA-FASTER\" HVF testing.\n* Patients who do not attend their outpatient clinic appointment,\n* Patients not able to perform visual field testing (for example due to their visual acuity, physical difficulty in positioning for test duration, or cognitive difficulties in understanding instructions).\n* Patients under the age of 18 years old.","99 Years",{"count":139,"type":21},100,[56],"The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss.\n\nThe WSFFM will be compared to the Humphrey Visual Field (HVF) analyser. The HVF analyser is the gold standard method of measuring visual fields; in our hospital eye service it is almost exclusively the method used, and as such the field technicians are particularly skilled in their use. The output data of the HVF enables easy quantification of level of field loss; by comparing the output from the WSFFM it would be possible to allow some form of quantification against \"the standard\" such that an idea of how well it works may be calculated.",[27],"2026-06-25",{"date":145,"type":37},"2026-06-29",{"date":147,"type":37},"2026-04-29",{"date":98,"type":21},{"name":150,"class":44},"Buckinghamshire Healthcare NHS Trust",{"id":152,"slug":4,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":179,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":219},"100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.",{"count":159,"type":21},500,[56],"This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[163,164,165,166,167,168,169,170,27,171,172,173,64,174,175,176,177,178],"Retinal Disease","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[180,181,182,183,184,185,186,187,188,163,177,189,190,191,192,193,194,195,196,197,165,166,198,199,200,176,170,169,167,201,202,203,204,205,206,207,208,209,171,172,210,178],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss",{"date":145,"type":37},{"date":213,"type":37},"2016-01",{"date":215,"type":21},"2028-07-31",{"name":217,"class":218},"MD Stem Cells","INDUSTRY",4,{"id":221,"slug":4,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":228,"phases":4,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":242},"100537189","NCT06274593","Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma","OGA","Inclusion Criteria:\n\n* Men and women aged 18 and over\n* Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital\n* mean visual field deficit (MD) \\>10dB\n\nExclusion Criteria:\n\n* Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR\u002FOBVR, OACR\u002FOBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...)\n* PPR (retinal PanPhotocoagulation), retinal cerclage\n* Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa)\n* AMD and other macular pathologies that can lead to central visual field deficits\n* Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract)\n* Loss of fixation point preventing visual field formation Pregnant or breast-feeding women\n* Protected adults under guardianship or curatorship\n* with unreliable visual fields (false positives and false negatives \\> 33%)\n* with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)",{"count":227,"type":21},50,"OBSERVATIONAL","Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.\n\nTo date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma.\n\nThe main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).",[27],[32,232,233],"OCTa","OCTrnfl","2026-06-23",{"date":39,"type":37},{"date":237,"type":37},"2024-04-27",{"date":239,"type":21},"2027-09",{"name":241,"class":44},"Nantes University Hospital",2,{"id":244,"slug":4,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100643945","NCT07668193","GlaukomAI: Clinical Validation of an AI System for Early Glaucoma Screening","GlaukomAI: Clinical Validation of an Artificial Intelligence-Based System for Early Glaucoma Screening and Diagnosis - A Case-Control Study and Referral Accuracy Assessment","GlaukomAIcare","Inclusion Criteria for all patients:\n\n* Age \\>18 years\n* Freely given informed consent obtained prior to study initiation\n* The participant has the capacity to understand and the willingness to follow study instructions and is likely to complete all required visits and procedures\n\nInclusion Criteria for glaucoma patients:\n\nPatients affected by any type of glaucoma (primary open-angle, primary angle-closure, secondary glaucoma) on pharmacological therapy\n\nInclusion Criteria for healthy controls:\n\n* Absence of ocular pathologies\n* IOP \\\u003C21 mmHg\n* Visual field and OCT within normal limits\n* Optic disc of normal appearance on clinical evaluation\n\nExclusion Criteria:\n\n* Presence of media opacities preventing the acquisition of adequate quality fundus imaging (e.g., advanced cataract, vitreous hemorrhage, severe corneal opacities)\n* Retinal or optic nerve pathologies that could confound the diagnosis (e.g., non-glaucomatous optic neuropathies (ischemic, inflammatory, compressive), moderate-to-severe diabetic retinopathy, advanced macular degeneration, retinal vascular occlusions)\n* Having undergone any ocular surgery in the past 3 months\n* Inability to cooperate with perimetric examination",{"count":251,"type":21},1200,[56],"Glaucoma is one of the leading causes of irreversible blindness worldwide. Early diagnosis is crucial to prevent vision loss, but current diagnostic pathways require multiple specialist visits and tests, leading to long waiting times and delayed diagnosis.\n\nThis study aims to evaluate the accuracy of GlaukomAI, an artificial intelligence (AI)-based software that analyzes fundus photographs of the eye to detect glaucoma at an early stage.\n\nThe study is conducted at IRCCS Fondazione G. B. Bietti (Rome, Italy) and is structured in two phases:\n\n* Phase 1 enrolls 200 participants (100 with diagnosed glaucoma and 100 healthy controls) to assess how accurately GlaukomAI can distinguish between glaucoma and healthy eyes, compared to the judgment of a panel of three expert glaucoma specialists.\n* Phase 2 enrolls 1,000 consecutive outpatients to evaluate whether GlaukomAI can correctly identify patients who need referral to a glaucoma specialist, and to compare its performance with that of non-specialist ophthalmologists.\n\nParticipants undergo a single study visit including standard ophthalmic examinations (visual acuity, eye pressure measurement, visual field test, OCT, and fundus photography). No investigational drugs or invasive procedures are involved.\n\nThe results of this study will provide evidence to support the integration of AI-based tools into routine glaucoma screening pathways, with the goal of reducing diagnostic delays and improving access to care.",[27],[27,256,257,258,259,260,261],"Artificial Intelligence","Fundus Photography","Glaucoma Screening","Early Diagnosis","Optic Nerve","GlaukomAI","NOT_YET_RECRUITING","2026-06-19",{"date":143,"type":37},{"date":266,"type":21},"2026-06",{"date":268,"type":21},"2028-05",{"name":270,"class":44},"Fondazione G.B. Bietti, IRCCS",{"id":272,"slug":4,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":4},"100644299","NCT07664943","The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence","Inclusion Criteria:\n\n* Age ≥ 18\n* Taking at least one glaucoma drop daily\n* A history of poor adherence when taking glaucoma eye drops. This is determined as an answer of 80% or less for the following question: \"Over the past month, what percentage of your drops do you think you took correctly?\"\n* Owns a functioning smart phone with Bluetooth and cellular connectivity\n\nExclusion Criteria:\n\n* Advanced cognitive impairment\n* Current or expected pregnancy during the study.",{"count":139,"type":21},[56],"Most patients with glaucoma use eye drops to lower their intraocular pressure. However, poor adherence to prescribed eye drop regimens can lead to significant loss of vision-related quality of life. This study will test the iDrop Device (iD2), a device-on-cap electronic platform monitor designed to accurately track when a research participant removes an eye drop bottle cap, wirelessly communicate usage data to a database accessible to researchers, and send on-demand alerts when a medication is due. A device capable of tracking eye drop usage and sending dosage alerts will test the hypothesis that electronic reminders improve medication adherence and help research subjects improve their eye drop taking behavior. While our primary focus is on glaucoma adherence, this device could also benefit those with other chronic eye conditions requiring regular eye drop treatment, such as dry eye, corneal endothelial disease, eye infections, and uveitis.",[27,280],"Medication Adherence",[282,283,284,27,285],"iD2","Adherence","Medication","Device","2026-06-17",{"date":39,"type":37},{"date":289,"type":21},"2026-09-01",{"date":101,"type":21},{"name":292,"class":218},"Universal Adherence LLC",{"id":294,"slug":4,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":45},"100642917","NCT07588152","Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension","Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of ocular hypertension or open-angle glaucoma\n* Eye examination within the past year\n* For glaucoma subjects: structural (optic nerve and\u002For retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma\n* Best-corrected visual acuity of 20\u002F100 or better\n* Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)\n* Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)\n\nExclusion Criteria:\n\n* Known intolerance to netarsudil ophthalmic solution\n* Corneal scarring or active corneal disease that would interfere with imaging\n* Inability to tolerate gonioscopy procedures\n* Females of childbearing potential who are not using effective contraception or are not sterile\n* Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion",{"count":227,"type":21},[301],"PHASE4","This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.",[27,304],"Ocular Hypertension","2026-06-09",{"date":307,"type":37},"2026-06-11",{"date":309,"type":37},"2026-06-05",{"date":311,"type":21},"2028-06",{"name":313,"class":44},"Indiana University",{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":320,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100643282","NCT07641296","Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension","Prospective, Multi-Center, Open-Label, Non-Randomized, Multi-Arm Study to Evaluate the Safety, Efficacy, and Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Implanted With a Posterior Chamber Intraocular Lens (PC-IOL) and Diagnosed With Mild to Moderate Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","Inclusion Criteria:\n\n* Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension\n* Pseudophakic or planned removal of cataract\n* Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease\n* History of incisional\u002Frefractive corneal surgery\n* Any glaucoma diagnosis other than OHT, open-angle, or pigmentary glaucoma\n* History of incisional glaucoma surgery\n* Other ocular diseases, pathology, or conditions","22 Years",{"count":322,"type":21},24,[324],"PHASE1","The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension. The main question it aims to answer is:\n\nDoes the BIM-DRS lower the pressure inside the eye to treat glaucoma or ocular hypertension?\n\nResearchers will compare two different doses of the BIM-DRS implanted either with a pre-existing commercially available monofocal intraocular lens (IOL) or concurrently with the SpyGlass IOL (IOL with silicone pads (no drug)).\n\nParticipants will:\n\n* Upon providing informed consent and successfully completing the screening visit, stop taking their IOP lowering medications in the eye to be treated.\n* Complete a baseline visit to further evaluate eligibility in the study eye.\n* Undergo surgery to implant the BIM-DRS (BIM-DRS and SpyGlass IOL for Cohorts 3 and 4). Only one eye of each participant will be treated.\n* Complete post-operative follow-up visits for evaluation at Day 1, Week 2, Week 6, Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 (last study visit).",[27,304],"2026-06-08",{"date":307,"type":37},{"date":330,"type":21},"2026-07-31",{"date":332,"type":21},"2030-03-31",{"name":334,"class":218},"SpyGlass Pharma, Inc.",{"id":336,"slug":4,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":342,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":358},"100593653","NCT07009236","A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma","A Multi-center, Prospective, Cohort Expansion Clinical Study Evaluating the Safety, Usability, Implantation Accuracy and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma (STAR VII Study)","STAR VII","Inclusion criteria\n\n1. Males or females, 20 years of age or older\n2. Diagnosis of open angle glaucoma (OAG) in the study eye\n3. Iridocorneal angle grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to Shaffer Angle Grading System in all quadrants of the study eye. (For subject's undergoing combined cataract extraction (with IOL implantation) with MINIject implantation, a grade 2 angle is acceptable prior to cataract surgery so long is the angle becomes grade 3 or greater prior to MINIject implantation).\n4. Glaucoma not adequately controlled with at least one topical hypotensive medication(s), unless the subject has an allergy \u002F intolerance to a medication or inability to consistently access medication. Examples include but are not limited to prostaglandins, beta blockers, carbonic anhydrase inhibitors or alpha-2-agonists\n5. Minimal visual acuity in the study eye must be 35 letters EDTRS (20\u002F200) or better and 50 letters ETDRS (20\u002F100) or better in the fellow eye\n6. Maximal C\u002FD ratio must be 0.9 in the study eye\n7. Subjects must be willing and able to follow study instructions and to return for scheduled study-related examinations\n8. Subjects must provide written informed consent prior to any study procedures\n9. Part 2 Only: Operable age-related cataract eligible for phacoemulsification surgery with Intraocular Lens (IOL) implantation\n10. Part 2 Only: The following intraoperative criteria following the IOL implantation need to be met in order for investigator to proceed with the investigational device placement:\n\n    1. Capsulorhexis is intact and centered\n    2. Posterior capsular bag is intact\n    3. The IOL is well-centered in the capsular bag\n    4. There is no evidence of zonular dehiscence\u002Frupture\n    5. The Anterior Chamber (AC) angle was able to be clearly visualized using direct gonioscopy.\n\nExclusion criteria\n\nSubjects are not eligible for inclusion in this clinical investigation if one or more of the following criteria are met:\n\n1. Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees) and grade 0 (closed or slit) iridocorneal angle according to Shaffer Angle Grading System in the study eye except for the situation described in inclusion criterion #3.\n2. Any eye surgery that was performed \\\u003C 90 days before Screening\u002FBaseline visit in the study eye\n3. Diagnosis of diabetes mellitus with HbA1C \\>7%\n4. Known or suspected allergy or hypersensitivity to medical silicone\n5. Allergy to fluorescein\n6. Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye, preventing correct placement of the implant\n7. Central endothelial cell density (ECD) at Screening visit with a mean value \\\u003C1900 cells\u002Fmm2 or coefficient of variation (CV) of endothelium \\>0.45 A variance of 5% less than this cell count is permitted if in the clinical judgement of the Investigator the potential benefit\u002Frisk to subject participation is favorable and the central corneal endothelial morphology is characterized as normal by the usual criteria of hexagonality, polymorphism, and polymegathism\n8. Anticipated need for ocular surgery or retinal laser procedure in the study eye\n9. Anterior chamber anatomic configuration of high risk for development of angle closure glaucoma in the study eye,\n10. Pre-existing ocular or systemic pathology that, in the opinion of the investigator (reason to be specified on the case report form), is likely to cause post-operative complications following implantation\n11. Central corneal thickness greater than 600 microns\n12. Clinically significant degenerative visual disorders that, in the opinion of the investigator, can impact study examinations (e.g. exudative macular degeneration or other retinal disorders)\n13. Clinically significant corneal disease (e.g., corneal dystrophy) in the study eye\n14. Evidence of crystalline lens subluxation or luxation in the study eye\n15. Inability to perform Visual Field (VF) testing in either eye\n16. Evidence of vitreous loss in the anterior chamber in the study eye\n17. Clinically significant intra-ocular inflammation or infection\n18. Presence of silicone oil in the study eye\n19. Participation in any study involving a drug or device within the past 3 months and planned participation to any other study during the present study. There is no exclusion period after completion of the present trial\n20. Only for women of childbearing potential: positive pregnancy test at Screening\u002FBaseline visit. Pregnant or lactating women\n21. Subject is under tutorship or trusteeship\n22. Subject has a condition such that his \u002F her ability to provide personal informed consent is compromised\n23. Diagnosis of cataract in the study eye that is not age-related e.g., traumatic, inflammatory or resulting from diabetes in the study eye\n24. Unable to discontinue anticoagulant\u002Fantiplatelet therapy (i.e. acetylsalicylic acid, coumadin, heparin, apixaban, etc.) for the surgical procedure. The amount of washout and when to restart therapy after surgery is at the Principal Investigator's discretion and may be based on literature references (see Annexes) or in consultation with the subject's primary care team.","20 Years",{"count":344,"type":21},60,[56],"This is a prospective, multi-center, international, cohort expansion study. Part 1 will be conducted in subjects with open angle glaucoma to identify the best insertion tool for MINIject S+. In Part 1, three different investigational insertion tools will be used to place MINIject implants in this first-in man study. Each arm represents a different version of the insertion tool. Subject and independent central reader will be blinded to the insertion tool used to implant MINIject S+. Part 2 will be an expansion phase where the selected insertion tool will be assessed in a larger population of subjects with open angle glaucoma and operable cataracts undergoing combined glaucoma and cataract surgery (with IOL implantation).",[27],[349],"MINIject",{"date":351,"type":37},"2026-06-10",{"date":353,"type":37},"2025-09-29",{"date":355,"type":21},"2028-07",{"name":357,"class":218},"iSTAR Medical",5,{"id":360,"slug":4,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":15,"sex":16,"minAge":366,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":45},"100343530","NCT03752840","Village-Integrated Eye Worker Trial II","Village-Integrated Eye Worker Trial II (VIEW II):A Cluster-randomized Trial of the Effectiveness of Community-based Ocular Disease Screening","VIEW II","Community level\n\nInclusion Criteria:\n\n* Located in catchment area of Bharatpur Eye Hospital or Lumbini Eye Institute\n* Reachable by non-4WD vehicle\n* Urban or peri-urban\n\nExclusion Criteria:\n\n\\- Local leaders unwilling to participate\n\nPerson level\n\nInclusion Criteria:\n\n* 60 years and older\n* Residing in the community during the time of the census\n\nExclusion Criteria:\n\n\\- Unwilling to participate","60 Years",{"count":368,"type":21},60200,[56],"The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). Loss of vision from these conditions is not inevitable; however, identifying cases early and linking cases with appropriate care remain significant challenges.\n\nTo address the global burden of avoidable blindness, eye care systems must determine optimal strategies for identifying people with or predisposed to visual impairment beyond opportunistic screening. Outreach programs can prevent blindness both by screening for asymptomatic disease like age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma and case detection of symptomatic disease like cataract and refractive error. Eye care systems have developed numerous approaches to these identification methods, including screening using telemedicine and case detection via cataract camps or health worker models, but no studies have been conducted on the comparative effectiveness or cost effectiveness of these various approaches.\n\nTechnology promises to greatly improve access to sophisticated eye care. AMD, DR, and glaucoma can result in irreversible vision loss, and early diagnosis and effective treatment can prevent progression. Thus, mass screening programs may prevent progression and improve the vision of a population. However, mass screening for eye disease is currently not recommended. Although self-evident that early detection can prevent blindness for an individual, no randomized controlled trial has been able to demonstrate that screening improves visual acuity at the regional level. However, recent technological advances promise to dramatically change the equation by allowing non-medical personnel to use mobile, easy-to-use retinal imaging devices to diagnose screenable eye diseases such as AMD, DR, and glaucoma. Mobile technology could also transform the way clinics communicate with their patients, improving linkage to and retention in care.\n\nOptical coherence tomography (OCT) is an ideal test for screening. OCT can be performed through an undilated pupil and is less subject to optical aberrations due to cataract than is fundus photography. OCT machines have pre-installed algorithms to screen for glaucoma, and major anatomical abnormalities can easily be detected even by novice technicians. The infrared image allows detection of referable diabetic retinopathy, and newer OCT angiography machines offer even more discrimination of early diabetic retinopathy. OCT machines are ever more portable, and could be feasibly used in mobile screening programs.\n\nThe investigators propose a large cluster-randomized trial to compare two population level blindness prevention programs: (1) a state-of-the-art screening program employing OCT, fundus photography, and intraocular pressure testing to screen for glaucoma, DR, and AMD followed by enhanced linkage-to-care to the local eye hospital, and (2) a screening program involving only visual acuity assessment. An initial door-to-door census will assess baseline visual acuity in both study arms. The investigators will compare visual acuity between the two arms through a second door-to-door census 9 years later (primary outcome).",[372,373,27],"Age-related Macular Degeneration","Diabetic Retinopathy",{"date":305,"type":37},{"date":376,"type":37},"2019-04-21",{"date":378,"type":21},"2029-08-31",{"name":380,"class":44},"University of California, San Francisco",{"id":382,"slug":4,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":45},"100628766","NCT07465913","Rocklatan vs Latanoprost Post-DSLT","Outcomes of Direct Selective Laser Trabeculoplasty With the Post-treatment Addition of Combination Netarsudil and Latanoprost vs Latanoprost Monotherapy","Inclusion Criteria:\n\n* Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG).\n* On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog.\n* Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes.\n* Best-corrected visual acuity (BCVA) ≥20\u002F60 in both eyes.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Ocular hypertension only (no glaucomatous damage).\n* Inability or medical ineligibility for washout of ocular hypotensive medications.\n* Prior selective laser trabeculoplasty (SLT) within 12 months of screening.\n* History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery \\[MIGS\\] affecting outflow).\n* Narrow or closed angles with gonioscopy (Shaffer grading ≤2).\n* Active ocular infection, uveitis, or severe dry eye.\n* Corneal pathology interfering with IOP measurement.\n* Advanced glaucoma (threat to fixation).\n* Known hypersensitivity to Rocklatan, latanoprost, or study medication components.\n* Pregnancy or lactation.",{"count":388,"type":21},36,[301],"This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.",[27],"2026-05-20",{"date":394,"type":37},"2026-05-22",{"date":396,"type":37},"2026-05-14",{"date":398,"type":21},"2027-05-06",{"name":400,"class":44},"Eye Centers of Southeast Texas",{"id":402,"slug":4,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":409,"briefSummary":410,"conditions":411,"keywords":412,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":45},"100640503","NCT07592988","Tear Interleukin Biomarkers After Glaucoma Treatment","Tear Fluid Interleukin Biomarkers and Intraocular Pressure Response After Micropulse Transscleral Cyclophotocoagulation, Conventional Cyclophotocoagulation, and Antiglaucoma Surgery in Patients With Glaucoma","TIGT","Inclusion Criteria:\n\n* Decision to treat by MP-CPC Laser\n* Patients diagnosed with Glaucoma\n* Patients aged 18 years old and above\n* Glaucoma that is inadequately controlled on medical therapy\n\nExclusion Criteria:\n\n* Patients age less than 18 years\n* Patients unable or unwilling to provide informed consent to participate in the study\n* Patients potentially unavailable for follow up visits\n* Patients with significant scleral thinning\n* Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study\n* Albino patients that have no iris pigmentation",{"count":322,"type":21},[56],"This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively.\n\nIntraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.",[27],[27,413],"Micropulse Laser","2026-05-12",{"date":416,"type":37},"2026-05-18",{"date":416,"type":21},{"date":419,"type":21},"2026-08-18",{"name":421,"class":422},"Kazakh Eye Research Institute","NETWORK",{"id":424,"slug":4,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":433,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":437,"leadSponsor":438,"locationsCount":45},"100638029","NCT07592923","Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation","Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation: The Influence of Choroidal Thickness on the Extent and Duration of the Hypotensive Effect","MMEMC",{"count":54,"type":21},[56],"This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.\n\nIntraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.",[27],[434,32],"micropulse laser",{"date":416,"type":37},{"date":416,"type":21},{"date":419,"type":21},{"name":421,"class":422},{"id":440,"slug":4,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":444,"targetDuration":4,"studyType":228,"phases":4,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":45},"100637940","NCT07580014","Choroidal and Retinal Features in PACD and POAG on OCT and OCTA","Inclusion Criteria:\n\n* Control group: Healthy individuals with no history of ocular surgery, IOP \\\u003C 21 mmHg, and CDR \\\u003C 0.5 bilaterally without asymmetry\n* Observation group: Glaucoma specialist-confirmed diagnosis of POAG or PACD (per ISGEO staging: PACS\u002FPAC\u002FPACG)\n\nExclusion Criteria:\n\n* History of retinal or macular disease (e.g., AMD, DR, RVO, ERM)\n* Non-glaucomatous optic neuropathy (e.g., MS, NMO)\n* Poor OCT\u002FOCTA image quality\n* Refusal to sign informed consent",{"count":445,"type":21},132,"Glaucoma is a group of irreversible, progressive optic neuropathies that can lead to severe visual field defects and even blindness, affecting nearly 95 million people worldwide. Based on anterior chamber angle structure, glaucoma is classified into primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). Although POAG is more common, PACG is more severe and more likely to cause blindness if not managed appropriately. Globally, PACG accounts for approximately 25% of all glaucoma cases but is responsible for roughly 50% of glaucoma-related blindness. Generally, the term \"glaucoma\" implies optic nerve damage; however, glaucomatous optic neuropathy may be absent in subacute and acute angle-closure glaucoma. Therefore, according to international consensus, primary angle-closure disease is categorized as PACD-encompassing primary angle-closure suspect (PACS), primary angle closure (PAC), and PACG-based on the extent of angle closure, intraocular pressure elevation, and optic nerve damage. With advances in ophthalmic imaging, an increasing array of diagnostic modalities has been applied to glaucoma diagnosis. Optical coherence tomography (OCT), which utilizes low-coherence light to display cross-sectional images of the retina in vivo, represents a rapid, non-invasive, and continuously evolving imaging method. Building upon OCT, OCTA has emerged as a novel imaging technique that allows non-invasive visualization and assessment of blood flow in individual retinal layers \\[5\\]. Existing OCT and OCTA research on glaucoma primarily focuses on the optic disc and macula of glaucoma patients, providing evidence of changes in the retinal nerve fiber layer, macular ganglion cell thickness, optic nerve head structure, and peripapillary and macular vasculature. Other studies have examined choroidal vascular architecture and thickness in glaucoma; previous findings from our research group also indicate that choroidal vascular density is significantly lower in eyes with POAG and PACG compared to normal eyes, while choroidal stromal area is significantly greater in PACG than in POAG eyes and normal controls. Further investigation into choroidal and retinal alterations in glaucoma is warranted. Consequently, the OCT and OCTA fundus characteristics of patients with PACD and POAG remain an area with unexplored unknowns. This study utilizes OCT and OCTA to observe the choroidal and retinal tissue structure and vascular hemodynamics in patients with PACD and POAG, aiming to comprehensively investigate structural changes in the glaucomatous fundus, broaden new research directions, and explore and supplement the understanding of glaucoma pathogenesis.",[27,448,449],"OCTA","Choroid","2026-05-06",{"date":414,"type":37},{"date":453,"type":37},"2024-07-16",{"date":455,"type":21},"2027-04-20",{"name":457,"class":44},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":459,"slug":4,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":228,"phases":4,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":474,"locationsCount":476},"100598691","NCT07074782","Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues: NEUROPA - a Retrospective Cohort Study","NEUROPA","Inclusion Criteria:\n\n* Age 18+ years\n* Established glaucoma diagnosis (primary open-angle glaucoma, normal tension Glaucoma, pseudoexfoliation glaucoma, pigmentary dispersion glaucoma) in either eye\n* Visual field mean deviation (MD; location-weighted mean difference from average age-corrected visual field sensitivity) of 2 visual fields differing by no more than 3 dB, for a mean deviation of better than -6.0 dB, or by no more than 4 dB, for a mean deviation worse than -6.0 dB, as measured using Humphrey perimetry (or equivalent Haag-Streit \u002F Octopus; in at least one eye; analogous to The United Kingdom Glaucoma Treatment Study)\n* Treatment with either prostaglandin analogues only or another topically applied IOP-lowering compound only for at least 3 years\n* Documented follow-up period of at least 3 years\n* At least 6 patient visits documented over the follow-up period with readings of IOP, visual field, OCT\n* No additional glaucoma intervention apart from laser trabeculoplasty and\u002For cataract surgery during the observational period\n\nExclusion Criteria:\n\n* Follow-up period \\\u003C 3 years\n* Number of patient visits \\\u003C6 visits\n* Number of OCT, visual field readings during the observation period \\\u003C 6\n* Low compliance\u002Ftherapy interruption\n* Beginning of combination therapy of prostaglandin analogues and other IOP lowering eye drops during the observation period\n* In case of glaucoma diagnosis in both eyes: different topical IOP-lowering treatment regimes (e.g. prostaglandin analogues in one eye and beta-adrenergic blocking agents in the fellow eye)\n* Additional glaucoma intervention during the observational period other than laser trabeculoplasty and\u002For cataract surgery",{"count":466,"type":21},1500,"The goal of this observational study is to evaluate whether prostaglandin analogue eye drops have a direct neuroprotective effect on retinal ganglion cells - beyond their intraocular pressure (IOP)-lowering effect - in adult patients with glaucoma or ocular hypertension. The study includes individuals diagnosed with glaucoma (any sex\u002Fgender, adult age groups) undergoing standard clinical treatment. The main questions it aims to answer are:\n\n* Do prostaglandin analogues provide a neuroprotective effect on retinal ganglion cells that is independent of their IOP-lowering properties?\n* Should prostaglandin analogues be promoted\u002Ffavoured over other IOP-lowering compounds for long-term glaucoma management?\n\nResearchers will compare an interventional group, which consist of 750 eyes treated with prostaglandin analogues (e.g., latanoprost, travoprost, tafluprost, bimatoprost, unoprostone), with a control group, which consist of 750 eyes treated with non-prostaglandin IOP-lowering compounds (e.g., timolol, dorzolamide, brimonidine, netarsudil) to see if treatment with prostaglandin analogues is associated with better retinal ganglion cell survival over a period of 3 years (36 months).\n\nData will be collected from individuals who had at least 36 months of documented follow-up, with clinical data available at approximately 3, 6, 12, 24, and 36 months. Eligible individuals must have been treated with either prostaglandin analogues or other intraocular pressure (IOP)-lowering agents as part of routine clinical care. The data to be obtained from medical records will include at least:\n\n* Intraocular pressure readings\n* Visual field testing\n* OCT measures\n* Visual acuity\n* Adverse events\n* Treatment adherence\u002Fcompliance\n* Additional glaucoma interventions",[27],"2026-05-05",{"date":450,"type":37},{"date":472,"type":21},"2026-05",{"date":266,"type":21},{"name":475,"class":44},"Association for Innovation and Biomedical Research on Light and Image",10,{"id":478,"slug":4,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":45},"100479487","NCT05523622","Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices","Inclusion Criteria:\n\n* Ability to provide signed and dated informed consent form. Patients willing to comply with all study procedures and be available for the duration of the study.\n\nMale or female patients aged 18 to 99 Patients in good general health as evidenced by ability to come to their appointment on day of study.\n\nExclusion Criteria:\n\n* Patients age less than 18 years Patients unable or unwilling to provide informed consent to participate in the study Patients for which an accurate tonometry reading cannot be performed. This may include those with blepharospasm (lid squeezers), nystagmus, extensive corneal pathology, or contact lens wearers who cannot remove their contact lens.Patients with significant scleral thinning Patients with a known allergy to proparacaine or fluorescein as these are used to anesthetize and allow measurement respectively of the eye when used with the Goldmann tonometer.",{"count":483,"type":21},300,[56],"We are testing the accuracy of Reichert's Tono-Vera tonometer by comparing measurements of IOP with this device and measurements with other commonly-used tonometers, including Goldmann Applanation and iCare.",[27],"2026-05-04",{"date":450,"type":37},{"date":490,"type":37},"2022-08-01",{"date":492,"type":21},"2027-12-31",{"name":494,"class":44},"State University of New York at Buffalo",{"id":496,"slug":4,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":4},"100635611","NCT07554937","Blinking Exercise Study","Optimizing Blinking Exercises to Improve Dry Eye Disease in Patients With Glaucoma","Inclusion Criteria:\n\n* 18 years of age or older.\n* Those in the intervention group must have a confirmed diagnosis of glaucoma and be using at least one topical antiglaucoma medication.\n* Control participants must be glaucoma suspects who have not yet commenced topical therapy.\n\nExclusion Criteria:\n\n• Glaucoma patients who have had ocular surgery within the previous six months, contact lens wear, systemic inflammatory or autoimmune diseases affecting the ocular surface, or other ocular surface disorders such as severe blepharitis or keratoconjunctivitis sicca.",{"count":502,"type":21},45,[56],"The goal of this clinical trial is to evaluate whether a structured blinking exercise can improve symptoms and signs of dry eye disease (DED) in adults with glaucoma who are using topical intraocular pressure-lowering medications. The study will also assess the effects of the intervention on tear film stability, blink function, and participant adherence to the exercise.\n\nThe main questions this study aims to answer are:\n\nDoes a two-week structured blinking exercise reduce dry eye symptoms, as measured by the Ocular Surface Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE) questionnaires? Does the blinking exercise improve objective measures of ocular surface health, including non-invasive tear break-up time (NITBUT) and blink dynamics?\n\nResearchers will compare glaucoma patients receiving topical medications (intervention group) with glaucoma suspects not using topical therapy (control group) to evaluate the effectiveness of the blinking exercise on dry eye outcomes.\n\nParticipants in both groups will receive instruction on a standardized blinking exercise protocol consisting of repeated close-squeeze-open blinking cycles performed three times daily for two weeks. Participants will attend study visits at baseline, 2 weeks (post-intervention), and 4 weeks (follow-up). At each visit, participants will complete validated dry eye questionnaires and undergo non-invasive assessments of tear film stability, blink characteristics, and meibomian gland function. Adherence to the blinking exercise will be monitored using self-reported logs or reminders.",[506,27],"Dry Eye Disease (DED)",[508,509,27,510,511,280],"Dry Eye Disease","Ocular Surface Disease","Blinking Exercise","Behavioral Intervention","2026-04-28",{"date":487,"type":37},{"date":515,"type":21},"2026-08",{"date":517,"type":21},"2027-03",{"name":519,"class":44},"St. Joseph's Healthcare Hamilton",{"id":521,"slug":4,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":16,"minAge":366,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":22,"phases":528,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":45},"100588607","NCT06943599","Strategies for Improving Linkage-to-Care After Eye Disease Screening","Village Integrated Eye Worker II Linkage-to-Care Trial","Inclusion Criteria:\n\n\\- Participant of the VIEW II study referred to the eye hospital at their eye screening visit.\n\nExclusion Criteria:\n\n* Residence in an area without reliable mobile connectivity",{"count":527,"type":21},3000,[56],"The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.",[189,373,27],[532,533,534,535],"Eye Diseases","mass screening","patient compliance","retention in care","2026-04-27",{"date":147,"type":37},{"date":539,"type":37},"2026-02-01",{"date":541,"type":21},"2028-06-30",{"name":380,"class":44},{"id":544,"slug":4,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":45},"100578056","NCT06806332","Glaucoma Drop Aids Part 2","Inclusion Criteria:\n\n* Currently on the same topical ophthalmic medications for treatment of glaucoma for a minimum of two months\n* Patient of Boston University Eye Associates\n\nExclusion Criteria:\n\n* Changed glaucoma medications within the past 2 months",{"count":549,"type":21},80,[56],"Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.",[27,553],"Intraocular Pressure",[555,556],"Eye drop aid","Nanodropper",{"date":512,"type":37},{"date":559,"type":21},"2026-07",{"date":561,"type":21},"2027-06",{"name":563,"class":44},"Boston Medical Center",{"id":565,"slug":4,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":581,"locationsCount":45},"100364366","NCT04024293","Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry","A Prospective Single Center Open Label Study Assessing Intraocular Pressure Measurements Using a Novel Sensing Contact Lens-based Device as Compared to Standard Tonometry, in Open Angle Glaucoma and Ocular Hypertensive Patients","Inclusion Criteria:\n\n* Informed Consent\n* A clinical diagnosis of primary open angle glaucoma (POAG), including normal tension glaucoma (NTG), for OAG patients\n* A clinical diagnosis of OHT, for OHT patients\n* For all patients:\n\nOpen angles on gonioscopy Aged ≥ 18 years, either gender Both central corneal radii (CCR) between 7.3mm (46.23D) and 8.05mm (41.93D), with a maximum difference of 2D between the 2 radii in the study eye Central corneal thickness (CCT) between 490µm and 600µm in the study eye\n\nExclusion Criteria:\n\n* Ocular pathology (other than glaucoma or OHT)\n* Previous glaucoma, cataract or refractive laser\u002Fsurgery\n* Corneal or conjunctival abnormality, precluding contact lens adaptation\n* Insufficiency of lacrimal secretion\n* Subjects with allergy to corneal anesthetic\n* Subjects with contraindications for silicone contact lens wear\n* Subjects with contraindications for Diamox or Latanoprost or Timolol\n* Skin irritations, skin eczema or other indications against the wearing of adhesive patches\n* Subjects unable or unwilling to comply with the study procedures\n* Subjects lacking the capacity to consent (vulnerable persons)\n* Subjects with history of cardiac failure, treated cardiopathy or renal failure\n* Subjects with known cognitive disorders\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Participation in another study with investigational drug within the 30 days preceding and during the present study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.",{"count":571,"type":21},12,[56],"While elevated intraocular pressure (IOP) is no longer part of the definition of glaucoma it remains the sole proven modifiable risk factor for the onset and progression of glaucoma.\n\nIOP is known to vary with the time of day as well as with daily activities. The importance of the nycthemeral IOP pattern for successful management of glaucoma has been well documented, especially for patients who experience visual loss despite apparently normal and\u002For controlled IOP during office hours.\n\nThe current way of assessing nycthemeral IOP fluctuation is to perform repeated discrete tonometry measurements, once per hour in the best cases. Since its development in the 50s, Goldmann applanation tonometry (GAT) has remained the gold standard method for measuring IOP, despite its limitations. However, tonometry may be an imperfect method for measuring changes in IOP because it allows only snapshot and non-continuous measurements, it is not physiologic and disturbs the sleep architecture.\n\nThere have been many efforts in the past decades to search for an ambulatory and frequent method to monitor IOP for 24 hours. In this context, Sensimed AG has recently developed a sensing contact lens-based device intended to measure IOP over 24 hours, the Goldfish (GF).\n\nFirst-in-man data obtained with this device showed agreements between IOP measured by GF and values obtained by standard tonometry in the same eye, comparable to literature results for routinely used tonometry devices. However, this pilot study included 9 subjects only with improvable safety, tolerability and efficacy profiles.\n\nThe main goal of this study is to assess IOP measurements with the GF and compare the values with those obtained by standard tonometry in patients with open angle glaucoma (OAG) and ocular hypertension (OHT).",[27,304],"2026-04-24",{"date":577,"type":37},"2026-04-30",{"date":579,"type":37},"2025-10-01",{"date":472,"type":21},{"name":582,"class":218},"Sensimed AG",{"id":584,"slug":4,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":15,"sex":16,"minAge":590,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":242},"100594099","NCT07015034","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice (DETECT)","DETECT","Inclusion Criteria:\n\n* +70 years\n* One or more chronic diseases\n* Are followed by GP du to chronic disease\n\nExclusion Criteria:\n\n* Dementia diagnosis\n* Known eye-diseases or are currently followed by private ophtalmologist\n* Not able to understand Danish","70 Years",{"count":592,"type":21},460,[56],"In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition. The main outcome is detection of vision impairment and secondary outcome is detection of conditions needing ophthalmologic follow-up but not presenting vision impairment at present time.",[596,27,164,597,373],"Vision Impairment and Blindness","Cataract","2026-04-23",{"date":147,"type":37},{"date":601,"type":37},"2024-05-15",{"date":603,"type":21},"2027-07-15",{"name":605,"class":44},"University of Copenhagen",{"id":607,"slug":4,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":611,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":45},"100380391","NCT04232982","The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis","Inclusion Criteria:\n\n* Adults patients\n* Able to give an informed consent\n* Capable of being followed during the study\n* Candidate for the Boston keratoprosthesis type I\n\nExclusion Criteria:\n\n* Patients younger than 18 years old or older than 80 years old\n* Unable to give an informed consent\n* Participating to another interventional glaucoma study\n* Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit.\n* Unable to wear a therapeutic contact lens secondary to eyelid malformation\n* Severe Ocular surface Disease with keratinization\n* Intra-ocular tumor\n* Terminal Glaucoma\n* Phthisis bulbi\n* Ocular albinism","80 Years",{"count":54,"type":21},[56],"The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success.\n\nGlaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure.\n\nIn order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye.\n\nThe transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis.\n\nOur hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis .\n\nMETHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist.\n\nFollowing their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.",[27,532,616],"Cornea Disease",[618,619,620,621],"Boston keratoprosthesis","Transscleral cyclophotocoagulation","Micropulse transscleral cyclophotocoagulation","G-Probe Transscleral cyclophotocoagulation",{"date":536,"type":37},{"date":624,"type":37},"2020-01-30",{"date":626,"type":21},"2036-12-01",{"name":628,"class":44},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":630,"slug":4,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":22,"phases":636,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":45},"100635660","NCT07555574","Defining Retinal Structures Using Hyperspectral Retinal Imaging","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Able to provide informed consent\n* Willing and able to attend a study visit at the Centre for Eye Research Australia\n* Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)\n* Age- and sex-matched healthy control participants without known retinal or optic nerve disease\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n* Known contraindication to pharmacological pupil dilation\n* History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe\n* Any condition that, in the investigator's opinion, would compromise participant safety or image quality",{"count":635,"type":21},1000,[56],"This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.\n\nApproximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.",[164,373,27,639,640],"Retinal Diseases","Healthy Volunteers","2026-04-21",{"date":147,"type":37},{"date":644,"type":37},"2025-01-01",{"date":646,"type":21},"2028-12-30",{"name":648,"class":44},"Center for Eye Research Australia",""]